Hovione has recently undergone six successful GMP inspections by major government agencies in the past eight months. The Japanese PMDA inspected sites in China and Portugal. The FDA inspected sites in Loures twice and New Jersey once. Also, the Portuguese authorities performed an inspection in April. The FDA inspected both NJ and Loures sites simultaneously, and no Form 483 was issued. The PMDA inspections were also successful.

The inspections are the result of client submissions for innovator drugs, generics, and devices using Hovione APIs or technologies that focus on particle properties in high-performing formulations.

“Our clients are thrilled. Successful outcomes at inspections is not an unusual event at Hovione, but to continue with this kind of stellar record in the current climate is something that makes us all really proud,” said Guy Villax, Hovione’s chief executive officer.